The Metabolic Syndrome




Prof Orit Pinhas-Hamiel


Pediatric Endocrine & Diabetes Unit Safra Children's Hospital Sheba Medical Center Tel-Aviv University Israel



What Me Worry?



Negative Effects of Obesity on Health



The Jolly Fat...





The Metabolically Healthy Obese (MHO)

 A unique subset of obese individuals that appear to be protected from development of metabolic disturbances associated with obesity

 They have large quantities of fat mass, but demonstrate remarkably favorable cardiovascular risk profiles

The Normal Weight Metabolically Obese (NWMO)

 NWMO persons are a subgroup of individuals who have normal weight and BMI, but display a cluster of obesity-related

abnormalities



Metabolic Syndrome

(Insulin Resistance Syndrome, Syndrome X)

- A clustering of cardiovascular risk factors that substantially increases the risk of
 - Cardiovascular disease
 - Type 2 diabetes
 - _n Cancer
 - Mortality

Metabolic Syndrome - Definition

National Cholesterol Education Program's Adult
Treatment Panel III report (**NCEP – ATPIII)**

> 3 must be present

- Central obesity
- Triglycerides > 150 mg/dl
- HDL < 40 mg/dl in men, < 50 mg/dl in women</p>
- Blood pressure > 130/80 mm/H
- Fasting glucose > 100 mg/dl

Metabolic Syndrome - Definition

WHO - 1999

- Impaired glucose tolerance (2 hour > 140)
- diabetes mellitus (fasting plasma > 126, 2 hour > 200)
- insulin resistance (highest quartile fasting insulin or HOMA score)

PLUS at least 2


- Blood pressure > 140/90 or on antihypertensive medication
- Triglyceride > 150 or HDL < 40 men, < 50 women</p>
- Central or general obesity BMI > 30 or WHR > 0.9 men, 0.85 women
- Microalbuminuria (> 20 mcg/min or albumin:creatinine > 30)

Metabolic Syndrome in children – Modified ATPIII

Criterion	Adults	Adolescents
Triglyceride	≥150	≥ 110
HDL	Males <40 Females < 50	≤ 40
Obesity	WC Males > 102 Females > 88	BMI or WC ≥ 90 th
Glucose	Fasting ≥ 100 2 hour ≥ 140	Fasting ≥ 100 2 hour ≥ 140
Blood pressure	≥ 130/85	≥ 90 th

Cook et al, Arch Pediatr Adolesc Med 157:821, 2003

Central Obesity






Central Obesity










Waist Measurement	At Increased Risk	At High Risk			
Men	>94 cm	>102 cm			
Women	>80 cm	>88 cm			

Waist Circumference






Central Obesity


 Abdominal obesity is associated with multiple cardiometabolic risk factors, including: dyslipidemia, elevated blood glucose, type 2 diabetes and inflammation – all factors leading to the development of cardiovascular disease

 Overall, 86% of abdominally obese patients had at least one other cardiometabolic risk factor (NHANES data on file).

Glucose Metabolism / Diabetes




Prediabetes



 Prediabetes is characterized by higher than normal blood glucose levels, either impaired fasting glucose or impaired glucose tolerance not yet high enough to be classified as diabetes

Hypertension



Hypertension

- A systolic blood pressure (SBP) >139 mmHg and/or
- A diastolic (DBP) >89 mmHg.
- Based on the average of two or more properly measured, seated BP readings.
- On each of two or more office visits


Table 1. Classification and management of blood pressure for adults *

				INITIAL DRUG THERAPY				
BP Classification	SBP [*] MMHG	DBP* MMHG	LIFESTYLE MODIFICATION	Without Compelling Indication	With Compelling Indications (See Table 8)			
Normal	<120	and <80	Encourage					
PREHYPERTENSION	120-139	or 80–89	Yes	No antihypertensive drug indicated.	Drug(s) for compelling indications.‡			
Stage 1 Hypertension	140-159	or 90–99	Yes	Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination.	Drug(s) for the com- pelling indications.‡ Other antihypertensive drugs (diuretics, ACEI,			
Stage 2 Hypertension	≥160	or ≥100	Yes	Two-drug combination for most [†] (usually thiazide-type diuretic and ACEI or ARB or BB or CCB).	ARB, BB, CCB) as needed.			

Dyslipidemia




Triglycerides



Triglycerides


 Elevated triglyceride levels, are stronger risk factors for heart disease in women than in men



 Diets high in refined carbohydrates, with carbohydrates accounting for more than 60% of the total energy intake, can increase triglyceride levels




 There is evidence that carbohydrate consumption causing a high glycemic index can cause insulin overproduction and increase triglyceride levels



 Heavy alcohol consumption can elevate triglycerides levels

HDL





HDL

Low HDL is an independent risk factor for CVD

 In contrast, high HDL levels are associated with longevity and are protective against the development of atherosclerotic disease

 In the Framingham Study, risk for CVD increases sharply as HDL below 40 mg/dL














Insulin Resistance



Acanthosis Nigricans



Prevalence of the Metabolic Syndrome

- Depends on
 - ethnicity and sex
 - the prevalence increases with age
 - —the prevalence increases with BMI
 - underlying disease

	BMI											
	≤	18.5 kg/r	m ²	18.6–23.9 kg/m ²			24.0–27.9 kg/m²			\geq 28.0 kg/m ²		
Metabolic status	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
Individual component												
High blood pressure	57.4	56.3	56.8	67.3	64.7	65.8	72.8	75.3	74.3	88.0	82.6	84.6
Hyperglycemia	21.3	32.4	28.0	40.9	44.7	43.1	57.4	54.6	55.8	64.1	61.4	62.4
Hypertriglyceridemia	4.3	11.3	8.5	12.1	25.8	20.1	26.9	36.1	32.3	31.5	43.7	39.4
Low HDL cholesterol	4.3	16.9	11.9	7.8	27.8	19.4	18.8	40.4	31.4	25.5	41.9	36.1
Central obesity	2.1	8.5	5.9	12.5	44.8	31.4	61.1	91.9	79.0	97.8	100	99.2
Metabolic syndrome	0	1.6	0.9	7.5	24.4	17.3	38.9	64.8	53.9	71.7	76.0	74.5
Numbers of components	20.1		-		22 E	212		22.4	250		100	100
≥1	68.1	77.5	73.7	79.2	88.5	84.6		98.4	96.9	100	100	100
≥2	17.0	35.2	28.0	42.4	68.5	57.8	77.0	90.1	84.6	96.2	95.2	95.6
≥3	4.3	9.9	7.6	13.3	33.4	25.0	46.4	65.8	57.6	72.8	76.0	74.9
≥4	0	2.8	1.7	4.3	14.6	10.3	16.6	33.4	26.4	29.9	43.4	38.6
5	0	0	0	0	2.5	1.5	2.4	10.7	7.2	8.2	15.0	12.5

Prevalence of Overweight, Obesity and Metabolic Syndrome Components in Multiple Sclerosis Patients with Significant Disability

Moran Livne

European Journal of Neurology

AIM

- To determine the prevalence of overweight and obesity, as assessed by BMI and cardiometabolic risk factors, in a cohort of adult patients with long duration of MS and significant disability
- We hypothesized that MS patients may be at increased risk to be heavier and to have components of the MetS, compared with the general population.

Obesity in MS

- Obesity may be increased among MS patients secondary to the deleterious effects of the disease:
 - These effects include frequent high dose steroid treatments
 - Decreased mobility and physical activity due to motor disability.

- The Sheba MS Center data registry was queried to identify patients according to the following:
 - diagnosis of MS according to Macdonald criteria
 - age 40 to 65 years
 - disease duration >10 years
 - neurological disability according to the Expended
 Disability Status Scale (EDSS) score ≥3.0

Demographic & clinical data accessed from database

- Gender, age, disease duration and EDSS
- Number of high dose steroid treatments
- The use of the following medications:
 - Antidepressants
 - Hypertension treatment
 - Oral anti diabetic medications
- Weight, height, waist circumference, and blood pressure are measured within the last three months
- Laboratory data, including fasting glucose, triglycerides (TG) and high density lipoprotein cholesterol (HDL-C) levels

 Prevalence rates of overweight and obesity in Israel were obtained from the first Israeli National Health and Nutrition Survey (MABAT)

Results

- The study population comprised 130 MS patients, 72.3 % females
- mean±SD age 55.8±6.0 years
- disease duration 18.2±10.1 years
- EDSS 5.5±1.0

Results

- Obesity was present in
 - 18.5% of disabled MS patients compared with
 - 28.3% in the general population (p<0.001)
- Overweight was present in
 - 34.6% of disabled MS patients compared with
 - -45.0% in the general population (p<0.001)
- Overall, 46.9% of MS patients were with normal weight compared to 27% in the age matched general population.

Rates of Obesity & Overweight

MS men pati	ents Gener	al population:
-------------	------------	----------------

Obesity	8.1%	24.9%	
Overweight	45.9%	50.7 %	

	MS women		General population	
Obesity		22.6%	33.1%	
Overweight		30.1%	38.7 %	

Within the MS population the prevalence of obesity was higher for females than for males, while the prevalence of overweight was lower for females than for males, similar to the trend observed in the general population

^{* (}p<0.001)

The MetS among MS Individuals

• 39 MS patients (30%) had the MetS

The MetS among MS Individuals

- There are no data on the prevalence of MetS in the general Israeli population
- Data of same age groups from other countries showed that 21-37 % of the general population have the MetS, according to the ATP III criteria

 Thus, our findings show similar rates of the MetS, despite lower rate of overweight and obesity.

The MetS among MS Individuals

- 39 MS patients (30%) had the MetS
- MS patients with the MetS compared with those without MetS were significantly
 - older (59.1±5.8 vs. 54.3±5.5 years, p<0.0001)
 - heavier (BMI 29.6 \pm 7. vs. 25.1 \pm 4.7 3 kg/m², p=0.001)
- no difference in
 - disease duration (17.7±9.9 vs. 18.5±10.2 years, p=0.6) or in
 - the number of steroid courses (6.5±10.1 vs. 6.4±8.2)

Components of the MetS

- 56.1% of disabled MS patients had central obesity by waist circumference
- 27.7 % were treated for hypertension
- 17.7% had elevated blood pressure
- 10% had type 2 diabetes mellitus
- 35.5% had fasting hyperglycemia
- 31.3% had treated dyslipidemia
- 26.1% had elevated TG level
- 28% had low HDL-C

Central Obesity in MS

 56% of MS patients had waist circumference consistent with abdominal obesity

 Abdominal obesity is a major risk factor for coronary heart disease and type 2 diabetes

 Indeed, patients with MS have been reported to have a 2.4 fold increased rate of deaths related to CVD than people without MS

Central Obesity in MS

 The paradox between lower prevalence of obesity & overweight but increased waist circumference suggests that the lower BMI is misleading as an indication of health

 This finding is supported by previous observations of lower ratios of muscle to fat in MS patients and individuals with other disabilities

Hypertension

 28% of the study population is treated for hypertension, corresponding to the reported prevalence in the general Israeli population

 Consistent with the finding of the NARCOMS study, in which 30% of patients with MS reported hypertension

Type 2 Diabetes

 10% of MS patients are diagnosed with T2DM, similar to the prevalence of 11.7% of the Israeli population ages 45-64 years



Dyslipidemia

- There are limited data on the prevalence of dyslipidemia in the general population in this age group in Israel, we could not assess the prevalence of MS patients compared with the general population
- Nevertheless as an adverse lipid profile was found to be associated with disability and progression in disability in subjects with MS

In Summary

- Increased waist circumference & other cardiovascular risk factors were found to be particularly prevalent among adult disabled MS patients, despite reduced rates of obesity and overweight
- This suggests that the lower BMI in this population is misleading in its association with health risk
- Our findings highlight the importance of guiding clinicians to follow waist circumference as a marker for potential cardiovascular risk among normal weight individuals with MS.

Overweight, Obesity and the Metabolic Syndrome in Type 1 Diabetes

Kaidar Kfir

Diabetes Metab Res Rev 31(1):76-84 ;2015

Type 1 Diabetes Mellitus

- Type 1 diabetes mellitus (T1DM) is one of the most prevalent chronic diseases of childhood, with a distinct risk factor for CVD
- Onset of atherosclerotic changes has been shown to appear early in T1DM patients
- Overweight and obesity have been found to be highly prevalent among children with T1DM and to be associated with cardiometabolic risk

^{*}Snell-Bergeon JK, Nadeau K (2012). J Cardiovasc Transl Res 5: 446-462

^{*} Jarvisalo MJ, Raitakari M, Toikka JO, et al. (2004). Circulation 109: 1750-1755

^{*} Liu LL, Lawrence JM, Davis C, et al. (2010) y. Pediatr Diabetes 11: 4-11

Aims

 Determine the prevalence of overweight and obesity among children, adolescents & young adults with type 1 diabetes (T1DM) compared to the general population

 Assess the prevalence of the metabolic syndrome (MetS) and its components

- ➤ Patients aged 5 to 30 years, diagnosed with T1DM and followed in the National Juvenile Diabetes Clinic, Maccabi Health Care Services, Raanana
- ➤ Definition of obesity and overweight by Centers for Disease Control and Prevention (CDC):
 - Overweight: 85th ≤ BMI < 95th percentile (1.036<Standard deviation score<1.645), or 25 ≤ BMI < 30 kg/m2
 - Obesity: BMI ≥ 95th percentile (SDSs ≥1.645), or BMI ≥ 30 kg/m2

Criteria for the metabolic syndrome:

- two or more of the following criteria:
 - BMI above the 97th percentile (z score, 2.0 or more)
 - Triglyceride level above the 95th percentile
 - HDL cholesterol level below the 5th percentile
 - Elevated blood pressures, defined as systolic and /or diastolic blood pressure above the 95th percentile for age and sex

^{*} Weiss R, Dziura J, Burgert TS, et al. (2004) . N Engl J Med 350: 2362-2374

^{*} Daniels SR, Greer FR (2008) Pediatrics 122: 198-208

^{* (1996)} Update on the 1987 Task Force Report on High Blood Pressure in Pediatrics 98: 649-658

Data obtained by chart review, 2012 - 2013:

- Gender
- Age of onset of diabetes
- Disease duration
- Weight, height, BMI percentiles, and BMI Z score
- Blood pressure
- Mode of diabetes treatment (pump or multiple daily injections (MDI)
- HbA1c level
- Triglycerides and HDL-C levels

Additional diseases:

- Hyper or hypothyroidism
- Celiac
- ADHD
- Medications:
 - Antidepressant
 - Hypertension treatment [angiotensin-converting enzyme (ACE) inhibitors / angiotensin receptor blockers (ARB)]
 - Ritalin

- > males and females separately
- > age groups:
 - 6 to <12 years (children)
 - 12 to <15 (younger adolescents)
 - 15 to <18 (older adolescents)
 - 18 to <25 (young adults)
 - and 25 to <34 (older adults)

> Databases:

- ➤ the 1st Israeli national health and nutrition survey (MABAT) for ages 12-15, 15-18 and adults aged 25-34 years
- data from nominees for military service in the Israel Defense Forces (IDF)
- Survey of Israeli schoolchildren aged 6-12 years

^[*] Keinan-Boker L, (2005) Isr Med Assoc J 7: 219-223

^{[*}Levin A, (2010) Weight disorders and associated morbidity among young adults in Israel 1990-2003. Pediatr Int 52: 347-352

^{[*} Huerta M, et al (2006): 1990-2000. Acta Paediatr 95: 444-449

Results: The study population

• 326 patients: 168 (51%) females; 158 (49%) males

 Age: mean 18.5±6.0 years median: 18.3 years (IQR 13.8-23.2)


Diabetes duration:

mean: 8.7±5.0 years (range 1.0-24.9)


median: 7.5 years (IQR 4.9-11.6)

• **HbA1c level**: 8.1±1.3 %


Obesity - males




Overweight - males



Obesity - Females



OVERWEIGHT - FEMALES



In summary

 The prevalence of overweight among older adolescents (15-18 years) & young adults (18-25 years) with T1DM was significantly higher than that of the general Israeli population

There were no obese T1DM females in the 15-18 year age group

 No association was found between the patients characteristics and the different weight groups

Metabolic Syndrome in Type 1 Diabetes

• 7% of all patients met the modified criteria for MetS

• The mean±SD HbA1c level of patients with MetS was 8.6±1.9 compared with those without the syndrome 8.0±1.3, p=0.14.

Prevalence of Metabolic Syndrome & its Parameters in T1DM

P value	Obesity %	Overweight	Normal weight		
		%	%	N	
0.0004	35.3	8.1	4.9	23	Metabolic syndrome
<0.0001					Hypertension
	52.9	22.6	13.6	56	Abnormal
	11.8	3.2	3.3	12	ACEi\ARB Treatment
0.04	17.7	9.7	4.5	20	low HDL
0.5	17.6	8.1	11.7	37	high triglycerides
0.003	11.8	0	0	2	BMI- Z score ≥2
0.1	18.8	16.1	8.2	33	low non HDL
0.04					LDL
	23.5	40.3	30.3	103	High
	23.5	9.7	5.7	24	Statin Treatment

Summary and Conclusions

- Overweight but not obesity was more prevalent in females with T1DM.
- MetS, hypertension and low HDL-C were more prevalent among overweight and obese individuals with T1DM than among normal weight individuals with T1DM
- These findings are important, as MetS and its components,
- mainly microalbuminuria, have been shown to predict
- coronary artery disease, renal failure and diabetes related
- death in T1DM patients

Thanks for Your Attention



